Payment overview · 2025
General Payments
$463.29
29 reported records · 8 companies
Healthcare provider profile · identity verified
Scott Reed, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · PINEHURST, ID · NPI 1326090754
Verified facts
What the public records show
CMS Open Payments records show Scott Reed, M.D. received $463.29 in general payments during 2025 across 29 reported records.
ABBVIE INC. accounted for 29.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Caplyta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Synthroid by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 103 claims for Eliquis by this doctor in 2024.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CAPLYTA as an associated drug or biological on 211855 records involving 46143 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Caplyta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $138.58 | 29.9% | 13 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $76.98 | 16.6% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $74.25 | 16.0% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $62.44 | 13.5% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $34.92 | 7.5% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $34.55 | 7.5% | 2 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $21.60 | 4.7% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $19.97 | 4.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $463.29 | 29 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $79.18 | 9 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $76.98 | 4 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $74.25 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $62.44 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $59.40 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $39.66 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $34.92 | 2 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $34.55 | 2 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $21.60 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $19.97 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CAPLYTA caplyta |
2025 | Caplyta | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
103 | 14 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) Exact reporting entity; no affiliate inference |
2025 | CAPLYTA open payments reported associated product |
CMS Open Payments — General Payments 211855 supporting records · 46143 recipient NPIs · example record 1241243071 |
Caplyta · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 353 | 46 |
| Amlodipine Besylate | Amlodipine Besylate | 309 | 47 |
| Duloxetine Hcl | Duloxetine Hcl | 299 | 39 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 294 | 44 |
| Atorvastatin Calcium | Atorvastatin Calcium | 269 | 41 |
| Benazepril Hcl | Benazepril Hcl | 236 | 43 |
| Bupropion Xl | Bupropion Hcl | 234 | 26 |
| Gabapentin | Gabapentin | 225 | 38 |
| Meloxicam | Meloxicam | 208 | 36 |
| Omeprazole | Omeprazole | 189 | 34 |
| Metformin Hcl | Metformin Hcl | 186 | 34 |
| Alprazolam | Alprazolam | 178 | 30 |
| Carvedilol | Carvedilol | 173 | 27 |
| Furosemide | Furosemide | 168 | 22 |
| Metoprolol Succinate | Metoprolol Succinate | 167 | 31 |
| Tamsulosin Hcl | Tamsulosin Hcl | 148 | 27 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 145 | 25 |
| Hydrochlorothiazide | Hydrochlorothiazide | 138 | 23 |
| Pregabalin | Pregabalin | 137 | 17 |
| Pantoprazole Sodium | Pantoprazole Sodium | 132 | 22 |
| Tramadol Hcl | Tramadol Hcl | 132 | 37 |
| Losartan Potassium | Losartan Potassium | 123 | 21 |
| Montelukast Sodium | Montelukast Sodium | 111 | 15 |
| Famotidine | Famotidine | 108 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 103 | 20 |
| Eliquis | Apixaban | 103 | 14 |
| Potassium Chloride | Potassium Chloride | 100 | 15 |
| Prednisone | Prednisone | 98 | 53 |
| Clopidogrel | Clopidogrel Bisulfate | 92 | 15 |
| Simvastatin | Simvastatin | 88 | 22 |
| Lisinopril | Lisinopril | 86 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 81 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 81 | suppressed |
| Lorazepam | Lorazepam | 79 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 76 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 74 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 70 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 67 | suppressed |
| Ozempic | Semaglutide | 67 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 61 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 59 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 58 | suppressed |
| Allopurinol | Allopurinol | 55 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 55 | 11 |
| Fentanyl | Fentanyl | 51 | 11 |
| Myrbetriq | Mirabegron | 51 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 50 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 49 | suppressed |
| Aripiprazole | Aripiprazole | 49 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 46 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 44 | 31 |
| Tizanidine Hcl | Tizanidine Hcl | 44 | 11 |
| Azithromycin | Azithromycin | 42 | 31 |
| Olanzapine | Olanzapine | 39 | suppressed |
| Rexulti | Brexpiprazole | 39 | suppressed |
| Celecoxib | Celecoxib | 36 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 35 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 32 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 32 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 32 | suppressed |
| Acyclovir | Acyclovir | 31 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 30 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 30 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 29 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 29 | suppressed |
| Clonazepam | Clonazepam | 28 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 28 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 28 | suppressed |
| Caplyta | Lumateperone Tosylate | 26 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 25 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 25 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 24 | suppressed |
| Lamotrigine | Lamotrigine | 23 | suppressed |
| Lansoprazole | Lansoprazole | 23 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 23 | suppressed |
| Metolazone | Metolazone | 22 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 22 | suppressed |
| Nabumetone | Nabumetone | 21 | suppressed |
| Cefdinir | Cefdinir | 20 | 18 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 20 | suppressed |
| Valsartan | Valsartan | 20 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 19 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 18 | suppressed |
| Glimepiride | Glimepiride | 18 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 18 | suppressed |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Diazepam | Diazepam | 17 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Estradiol | Estradiol | 17 | suppressed |
| Ezetimibe | Ezetimibe | 17 | suppressed |
| Mirtazapine | Mirtazapine | 17 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 17 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 16 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 16 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 16 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 16 | suppressed |
| Spironolactone | Spironolactone | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | 14 |
| Hydromorphone Hcl | Hydromorphone Hcl | 15 | suppressed |
| Niacin Er | Niacin | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Synthroid | Levothyroxine Sodium | 15 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 15 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 15 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Dulera | Mometasone/Formoterol | 14 | suppressed |
| Indomethacin | Indomethacin | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 13 | suppressed |
| Dayvigo | Lemborexant | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Methadone Hcl | Methadone Hcl | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 13 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 13 | suppressed |
| Oxycontin | Oxycodone Hcl | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 13 | suppressed |
| Atenolol | Atenolol | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Hysingla Er | Hydrocodone Bitartrate | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Movantik | Naloxegol Oxalate | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $463.29 · 29 records | ABBVIE INC. | CAPLYTA, COBENFY, EVENITY, FANAPT, GEMTESA, JOURNAVX, QULIPTA, UBRELVY, VRAYLAR, XIFAXAN | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Caplyta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error